Experts concerned over mixed results from Takeda’s dengue vaccineTakeda’s dengue vaccine has met its target of protection against the disease in children – but there are Share XExperts concerned over mixed results from Takeda’s dengue vaccinehttps://pharmaphorum.com/news/experts-concerned-over-mixed-results-from-takedas-dengue-vaccine/
Sanofi builds case for Toujeo in younger type 1 diabeticsSanofi’s Toujeo – a follow-up to its long-acting insulin drug Lantus – has underperformed commercially since launch but Share XSanofi builds case for Toujeo in younger type 1 diabeticshttps://pharmaphorum.com/news/sanofi-builds-case-for-toujeo-in-younger-type-1-diabetics/
Sanofi settles dispute with Genzyme investors over MS drugSanofi has settled a long-running dispute with shareholders in the biotech Genzyme, who claimed the big pharma deliberately Share XSanofi settles dispute with Genzyme investors over MS drughttps://pharmaphorum.com/news/sanofi-settles-dispute-with-genzyme-investors-over-ms-drug/
Regeneron/Sanofi get EU okay for Dupixent in “asthma of the sinuses”Regeneron and Sanofi’s immunology drug Dupixent has been approved for a third indication in Europe, adding the treatment Share XRegeneron/Sanofi get EU okay for Dupixent in “asthma of the sinuses”https://pharmaphorum.com/news/regeneron-sanofi-get-eu-okay-for-dupixent-in-asthma-of-the-sinuses/
Pfizer’s Xeljanz follow-up abrocitinib gathers momentumPfizer has reported new data with abrocitinib, a follow-up to its JAK inhibitor Xeljanz, which is facing increased Share XPfizer’s Xeljanz follow-up abrocitinib gathers momentumhttps://pharmaphorum.com/news/pfizers-xeljanz-follow-up-abrocitinib-gathers-momentum/
Sanofi opens digital biologics manufacturing siteSanofi has opened a manufacturing facility in the US, one of the world’s first facilities using digital continuous Share XSanofi opens digital biologics manufacturing sitehttps://pharmaphorum.com/news/sanofi-opens-digital-biologics-manufacturing-site/
The digital future: Sanofi’s Marc SchwartzIn this series we speak to pharma leaders to get their views on the biggest trends in digital Share XThe digital future: Sanofi’s Marc Schwartzhttps://pharmaphorum.com/digital/the-digital-future-sanofis-marc-schwartz/
Sanofi’s Dupixent backed for nasal polyps use in EuropeSanofi and Regeneron’s fast-growing immunology drug Dupixent is on course for a third indication in Europe after being Share XSanofi’s Dupixent backed for nasal polyps use in Europehttps://pharmaphorum.com/news/sanofis-dupixent-backed-for-nasal-polyps-use-in-europe/
Novo and Sanofi make case for hypo-reducing insulins at EASDNovo Nordisk and Sanofi have gone head-to-head at this week’s European diabetes conference, with the two arch rivals Share XNovo and Sanofi make case for hypo-reducing insulins at EASDhttps://pharmaphorum.com/news/novo-and-sanofi-duke-it-out-at-easd-making-case-for-hypo-reducing-insulins/
